1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Levetiracetam |
| brand | String | Keppra (IR), Keppra XR, Spritam (3D-printed orally disintegrating), Roweepra |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Anticonvulsants|Anticonvulsant]] • [[:Category:SV2A ligands|Synaptic vesicle protein 2A (SV2A) ligand]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"' |
| starting_dose | String | Adult: 500 mg PO BID, titrate by 1000 mg/day every 2 weeks. Pediatric: 10-20 mg/kg/day divided BID, weight-titrated |
| preparations | String | IR tablets 250, 500, 750, 1000 mg; XR tablets 500, 750 mg; oral solution 100 mg/mL; injection 100 mg/mL; Spritam ODT 250, 500, 750, 1000 mg |
| fda_max | String | 3000 mg/day |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • intravenous |
| onset | String | Anticonvulsant effect within days at therapeutic plasma level; rapid titration possible |
| duration | String | BID dosing (IR); once-daily (XR) |
| halflife | String | 6-8 hours'"`UNIQ--ref-0000001F-QINU`"' |
| bioavailability | String | ~100% (oral)'"`UNIQ--ref-00000020-QINU`"' |
| pregnancy | String | '''Considered one of the safest anticonvulsants in pregnancy''', with reassuring monotherapy registry data comparable to lamotrigine and in sharp contrast to valproate, topiramate, and carbamazepine'"`UNIQ--ref-00000021-QINU`"' |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance'"`UNIQ--ref-00000022-QINU`"' |
